Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Rituximab for Wet AMD
NCT02332941Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2014
- Primary completion
- Jun 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rituximab in exudative macular degeneration, sponsored by Washington University School of Medicine. Primary endpoint: Central Macular Thickness at 2 years. Started Aug 2014; status: completed.
02
Drugs
rituximab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT02332941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02332941.